CagriSema vs. Zepbound
The Incoming Challenger vs. Today's Weight Loss Champion
Zepbound (tirzepatide) produces around 20% weight loss. CagriSema — a GLP-1 + amylin combination from Novo Nordisk — showed 22–24% in trials. FDA decision expected 2026. Here's how they compare.
| Feature | CagriSema | Zepbound |
|---|---|---|
| Active Ingredients | Cagrilintide + Semaglutide | Tirzepatide |
| Mechanism | GLP-1 + Amylin receptor | GLP-1 + GIP receptor |
| Phase 3 Weight Loss | 22–24% | ~20% |
| Injection Frequency | Once weekly | Once weekly |
| FDA Status | Decision expected 2026 | Approved |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Muscle Preservation | Under study | Under study |
GLP-1 + Amylin vs GLP-1 + GIP — Why It Matters
CagriSema: GLP-1 + Amylin
Amylin is a naturally occurring hormone co-secreted with insulin from pancreatic beta cells. It independently slows gastric emptying, suppresses glucagon, and reduces appetite via the brainstem — entirely separate from the GLP-1 pathway.
Adding cagrilintide (amylin analog) to semaglutide creates synergistic appetite suppression through two different hormonal systems simultaneously.
Zepbound: GLP-1 + GIP
GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone that enhances insulin secretion, reduces glucagon, and also acts on fat cells and the brain to further suppress appetite and promote energy expenditure.
Tirzepatide's dual GLP-1/GIP mechanism was the breakthrough that made it produce greater weight loss than any single-agonist GLP-1 drug before it.
FAQ
How does CagriSema compare to Zepbound for weight loss?
CagriSema showed 22–24% weight loss in Phase 3 vs ~20% for Zepbound at max dose. The difference is meaningful but not dramatic. CagriSema uses a different mechanism (amylin) which may benefit patients who don't respond optimally to GIP-based drugs.
When will CagriSema be approved?
Novo Nordisk submitted the FDA application in 2025, with a decision anticipated in 2026. As with all FDA reviews, approval timelines can shift.
Can I track CagriSema on Shotlee?
Yes — Shotlee already supports CagriSema tracking with weekly injection logging, dose progression, and weight monitoring. You can start tracking before approval if you're in a clinical trial.
Track Today's and Tomorrow's Medications
Shotlee supports both Zepbound and CagriSema. Switch when your medication changes — your history stays.
🚀 Get Shotlee Free